⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4111664 | 1.00 | — | — | |
| SCHEMBL13854600 | 1.00 | — | — | |
| SCHEMBL278851 | 1.00 | — | — | |
| SCHEMBL18959162 | 1.00 | — | — | |
| SCHEMBL14346345 | 1.00 | — | — | |
| SCHEMBL20413233 | 1.00 | — | — | |
| SCHEMBL14346370 | 1.00 | — | — | |
| SCHEMBL14346348 | 1.00 | — | — | |
| SCHEMBL12582830 | 1.00 | — | — | |
| SCHEMBL13225704 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148449-A1 | Substituted-Quinoxaline-Type Bridged-Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. | 2018-05-31 | — | — | US | disclosed |
| US-20180066370-A1 | CO2 REDUCTION CATALYST, CO2 REDUCTION ELECTRODE AND CO2 REDUCTION DEVICE | KABUSHIKI KAISHA TOSHIBA (JP) | 2018-03-08 | — | — | US | disclosed |
| US-9890164-B2 | Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators | PURDUE PHARMA, L.P. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170166598-A1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMACEUTICALS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20160009717-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2016-01-14 | — | — | US | disclosed |
| US-9145408-B2 | Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators | PURDUE PHARMA L.P. (US) | 2015-09-29 | — | — | US | disclosed |
| US-8758767-B2 | Antigens targeted by prevalent pathogennic T cells in type 1 diabetes and uses thereof | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130274265-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2013-10-17 | — | — | US | disclosed |
| US-8476271-B2 | Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators | PURDUE PHARMA, L.P. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110178090-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2011-07-21 | — | — | US | disclosed |
| US-20080305962-A1 | Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080153112-A1 | Antigens Targeted by Prevalent Pathogennic T Cells in Type 1 Diabetes and Uses Thereof | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2008-06-26 | — | — | US | disclosed |
| US-7199099-B2 | Methanobactin: a copper binding compound having antibiotic and antioxidant activity isolated from methanotrophic bacteria | THE UNIVERSITY OF KANSAS (US) | 2007-04-03 | — | — | US | disclosed |